These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15304558)

  • 1. Allosteric modulators: the new generation of receptor antagonist.
    Kenakin T
    Mol Interv; 2004 Aug; 4(4):222-9. PubMed ID: 15304558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosteric modulators of metabotropic glutamate receptors: lessons learnt from mGlu1, mGlu2 and mGlu5 potentiators and antagonists.
    Johnson MP; Nisenbaum ES; Large TH; Emkey R; Baez M; Kingston AE
    Biochem Soc Trans; 2004 Nov; 32(Pt 5):881-7. PubMed ID: 15494040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allosteric properties of G protein-coupled receptor oligomers.
    Springael JY; Urizar E; Costagliola S; Vassart G; Parmentier M
    Pharmacol Ther; 2007 Sep; 115(3):410-8. PubMed ID: 17655934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for positive allosteric modulators of biological targets.
    Groebe DR
    Drug Discov Today; 2006 Jul; 11(13-14):632-9. PubMed ID: 16793532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential.
    Kew JN
    Pharmacol Ther; 2004 Dec; 104(3):233-44. PubMed ID: 15556676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seven transmembrane receptors as nature's prototype allosteric protein: de-emphasizing the geography of binding.
    Kenakin TP
    Mol Pharmacol; 2008 Sep; 74(3):541-3. PubMed ID: 18583453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allosteric ligands for the corticotropin releasing factor type 1 receptor modulate conformational states involved in receptor activation.
    Hoare SR; Fleck BA; Gross RS; Crowe PD; Williams JP; Grigoriadis DE
    Mol Pharmacol; 2008 May; 73(5):1371-80. PubMed ID: 18239030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The endogenous allosteric regulators of receptors].
    Balashov AM
    Usp Fiziol Nauk; 2004; 35(2):73-91. PubMed ID: 15174297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allosteric enhancers, allosteric agonists and ago-allosteric modulators: where do they bind and how do they act?
    Schwartz TW; Holst B
    Trends Pharmacol Sci; 2007 Aug; 28(8):366-73. PubMed ID: 17629958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology.
    Leach K; Sexton PM; Christopoulos A
    Trends Pharmacol Sci; 2007 Aug; 28(8):382-9. PubMed ID: 17629965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allosteric modulation of 5-HT(1A) receptors by zinc: Binding studies.
    Barrondo S; Sallés J
    Neuropharmacology; 2009 Feb; 56(2):455-62. PubMed ID: 18951909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The NMDA receptor complex: a long and winding road to therapeutics.
    Wood PL
    IDrugs; 2005 Mar; 8(3):229-35. PubMed ID: 15772895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New concepts in drug discovery: collateral efficacy and permissive antagonism.
    Kenakin T
    Nat Rev Drug Discov; 2005 Nov; 4(11):919-27. PubMed ID: 16264435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Muscarinic allosteric modulators: atypical structure-activity-relationships in bispyridinium-type compounds.
    Sürig U; Gaal K; Kostenis E; Tränkle C; Mohr K; Holzgrabe U
    Arch Pharm (Weinheim); 2006 Apr; 339(4):207-12. PubMed ID: 16572483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allosteric modulation of G protein-coupled receptors: perspectives and recent developments.
    Soudijn W; Van Wijngaarden I; IJzerman AP
    Drug Discov Today; 2004 Sep; 9(17):752-8. PubMed ID: 15450241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allosterism and cannabinoid CB(1) receptors: the shape of things to come.
    Ross RA
    Trends Pharmacol Sci; 2007 Nov; 28(11):567-72. PubMed ID: 18029031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determining the potency and molecular mechanism of action of insurmountable antagonists.
    Kenakin T; Jenkinson S; Watson C
    J Pharmacol Exp Ther; 2006 Nov; 319(2):710-23. PubMed ID: 16857731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors.
    May LT; Avlani VA; Langmead CJ; Herdon HJ; Wood MD; Sexton PM; Christopoulos A
    Mol Pharmacol; 2007 Aug; 72(2):463-76. PubMed ID: 17525129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. '7TM receptor allostery: putting numbers to shapeshifting proteins.
    Kenakin TP
    Trends Pharmacol Sci; 2009 Sep; 30(9):460-9. PubMed ID: 19729207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators.
    Ritzén A; Mathiesen JM; Thomsen C
    Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):202-13. PubMed ID: 16176554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.